TolerRx, Inc. company develops therapies to treat patients with autoimmune diseases, including Type I diabetes and rheumatoid arthritis. Organ transplant rejection is also a target. The company's treatments induce immunological tolerance, or teach a body's immune system to recognize its own tissues and prevent it from attacking the tissue and causing disease. TolerRx has five autoimmune and two cancer/chronic viral drugs in the pipeline. The immune drugs include treatments for Type I diabetes, psoriasis, rheumatoid arthritis, and lupus. TolerRx was founded in 2000 by Herman Waldmann and Douglas J. Ringler.

Daiichi Sankyo Company, Limited is a Japan-based holding company mainly engaged in the manufacturing and sale of pharmaceuticals. The Company has two business segments. The Pharmaceuticals segment is involved in the research, development, manufacturing and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical making. The Others segment is involved in the real estate leasing, the insurance agency business, as well as the provision of human affairs and accounting services.

Spectrum Pharmaceuticals, Inc. operates as a commercial-stage biotechnology company with a primary focus in oncology market. The company focuses on acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma; and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. The company also develops apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products comprise Ozarelix, a drug being investigated for benign prostatic hypertrophy, a non-cancerous enlargement of the prostate; and Ortataxel, a third-generation taxane. In addition, Spectrum Pharmaceuticals, Inc. has exclusive worldwide rights to Renazorb, Renalan, and related compounds. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Its cancer drug Velcade is approved as a treatment for multiple myeloma (a type of blood cancer) and Mantle Cell Lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). The company has more than a dozen other candidates in the pipeline, most of them cancer-related. Millennium's oncology-focused sales force, in partnership with Johnson & Johnson subsidiary Ortho Biotech, sells the drug in the US; Ortho Biotech is responsible for sales in Europe and in other countries where Velcade is approved (except Japan, which is covered by Janssen). Takeda Pharmaceutical acquired Millennium Pharmaceuticals for $8.8 billion in 2008.

Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas. Opexa Therapeutics, Inc. operates as a biopharmaceutical company, developing autologous cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS) and diabetes. These therapies are based on Opexa's proprietary T-cell and adult stem cell technologies. The company's products include a T-cell therapeutic vaccine, Tovaxin, which is in clinical development for the treatment of MS. The adult stem cell technology is in the preclinical development stage. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

Founded in 1981, Generics (UK) Limited is a subsidiary of Mylan, the world's third largest generic drug maker. Generics (UK) Limited covers the pharmaceutical business. The name pretty much says it all. Generics (UK) Limited is one of the UK's largest generic pharmaceutical manufacturers, offering a line of more than 350 products sold to pharmacy retailers, hospitals, and wholesale customers. The company makes generic equivalents of such drugs as acid reflux remedy Pepcid, antibiotic Cipro, and allergy treatment Zyrtec.

Monogram Biosciences, Inc. Diagnostics company operates in the growing field of personalized medicine, creating laboratory tests that help doctors tailor treatments for infectious disease and cancer patients based on the patients' genetic traits. Its PhenoSense and GenSeq tests determine patients' drug resistance to various classes of HIV drugs. It has also introduced its Trofile assay, which helps doctors choose patients who will be responsive to a new class of HIV drugs called CCR5 antagonists. Monogram markets its products to doctors and reference laboratories (for patient treatment) and to drug researchers (for clinical trials). The company was acquired by LabCorp in 2009.

Chesapeake PERL was founded in 2000. Chesapeake PERL calls a "mini bioreactor" to produce proteins. Using its PERLXpress technology platform, the company mass produces antibodies, enzymes, viral antigens, and other proteins in whole insect larvae. It sells its custom protein development services, as well as some research reagents, to biotech concerns, including drug and diagnostics companies, biotech instrument makers, agricultural companies, and makers of industrial enzymes. It has also received federal grants from the NIH, the US Army, and the US Department of Energy.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.